Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699639 | 1.00 | LPL (0.36) | LPLLIPGSNCABTKEGFR | |
| SCHEMBL12615775 | 0.82 | LPL (0.33) | LPLLIPG | |
| SCHEMBL26653581 | 0.81 | LPL (0.33) | LPLLIPG | |
| SCHEMBL31149580 | 0.80 | SNCA (0.38) | LPLLIPGSNCADGAT1 | |
| SCHEMBL18342256 | 0.79 | LPL (0.39) | LPLLIPGIRAK4 | |
| SCHEMBL31631018 | 0.79 | LPL (0.39) | LPLLIPGIRAK4 | |
| SCHEMBL4211647 | 0.78 | LPL (0.40) | LPLLIPGDGAT1IRAK4CA1 | |
| SCHEMBL31580881 | 0.77 | DGAT1 (0.47) | LPLLIPGDGAT1 | |
| SCHEMBL1403776 | 0.77 | BRD4 (0.36) | LPLLIPG | |
| SCHEMBL17268323 | 0.77 | CCR1 (0.45) | LPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637427-B2 | ALDH-2 inhibitor compounds and methods of use | AMYGDALA NEUROSCIENCES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | H. LUNDBECK A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250263422-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2025-08-21 | — | — | US | disclosed |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| EP-4540228-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | Amygdala Neurosciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240425521-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2024-12-26 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| WO-2008076045-A1 | NOVEL 2-AMINO- 5-ARYL-IMIDAZOL-4 -ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | MAPT, PSEN1, PSEN2 | LPL 3742/4885LIPG 3896/4885SNCA 33/4885 |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | LPL 2097/4885LIPG 2029/4885SNCA 2631/4885 |
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | LPL 3355/4885LIPG 3428/4885SNCA 3332/4885 |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | LPL 5/4885LIPG 14/4885SNCA 4028/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | LPL 4428/4885LIPG 4384/4885SNCA 4334/4885 |
| US-12590106-B2 | Spiromacrocyclic orexin 2 receptor agonists | HCRTR2, HCRTR1, OXER1 | LPL 4553/4885LIPG 4598/4885SNCA 2821/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | LPL 4564/4885LIPG 4736/4885SNCA 424/4885 |
| US-12637427-B2 | ALDH-2 inhibitor compounds and methods of use | ALDH3A1, ALDH1A1, ALDH1A2 | LPL 188/4885LIPG 2359/4885SNCA 1746/4885 |
| US-20250263422-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | LPL 4053/4885LIPG 4524/4885SNCA 3068/4885 |
| US-20240425521-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | LPL 4053/4885LIPG 4524/4885SNCA 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.